Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 Infection

Intervirology

Volumn 52, Issue 1, 2009, Pages 49-56

  Iuliano, A Danielle ^a   Feingold, Eleanor ^a   Wahed, Abdus S ^a   Kleiner, David E ^d   Belle, Steven H ^a   Conjeevaram, Hari S ^c   Zmuda, Joseph ^a   Liang, T Jake ^e   Yee, Leland J ^a,b,f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f NONE   (United States)

Author keywords

Hepatitis C virus; Host genetics; Insulin resistance; Steatosis

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; GENETIC VARIABILITY; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STEATOSIS;

ADULT; AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FATTY LIVER; FEMALE; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERLEUKINS; MALE; MIDDLE AGED; RECEPTORS, LEPTIN; TRANSFORMING GROWTH FACTOR BETA1; UNITED STATES;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 65449161788     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214380     Document Type: Article

References (28)

1. Teli MR, James OF, Burt AD, Bennett MK, Day CP: The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (Ba ltimore, Md.) 1995; 22: 1714-1719.
2. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F: Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55:123-130.
3. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al: Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131:470-477.
4. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al: Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80-87.
5. Hui JM, Kench JG, Farrell GC, Lin R, Samarasinghe D, Liddle C, et al: Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17:873-881.
6. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-490.
7. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of et hnicity. Hepatology 2004; 40: 1387-1395.
8. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
9. Ruhl CE, Everhart JE: Epidemiology of nonalcoholic fatty liver. Clin Liv Dis 2004; 8:501-519, v ii.
10. Fabris P, Floreani A, Carlotto A, Baldo V, Bozzola L, Giordani MT, et al: Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin. Aliment Pharmacol Ther 2005; 21: 1173-1178.
11. Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, et al: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007; 14 : 29-35.
12. Rao G: Insulin resistance syndrome. Am Fam Phys 2001; 63: 1159-1166.
13. Romero-Gomez M: Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075-7080.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
15. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al: Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterolog y 2003; 125: 1695-1704.
16. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-641.
17. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al: Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: 279-283.
18. Yee LJ, Tang YM, Kleiner DE, Wang D, Im K, Wahed AS, et al: Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C v irus. Hepatology 2007; 46: 74-83.
19. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al: Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
20. Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21:2191-2192.
21. Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
22. Su X, Yee LJ, Im K , Rhodes S , Tang YM, Tong X, et al: Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol 2008;49: 184-191.
23. Barrett JC, Fry B, Maller J, Daly MJ: Haplo-view: analysis and visualization of LD and haplotype maps. Bioinformatics (Oxford, England) 2005; 21:263-265.
24. Narita R, Abe S , Tabaru A , Otsuki M: Impact of steatosis on insulin secretion in chronic hepatitis C patients. Am J Gastroenterol 2007; 102:2173-2180.
25. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, et al: FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006; 34(web server issue):W635-W641.
26. Cardellini M, Perego L, D'Adamo M, Marini MA, Procopio C, Hribal ML, et al: C-174G polymorphism in the promoter of the inter-leukin-6 gene is associated with insulin resistance. Diabetes Care 2005; 28:2007-2012.
27. Testa R, Olivieri F, Bonfigli AR, Sirolla C, Boemi M, Marchegiani F, et al: Interleukin-6-174 G>C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2006; 71: 299-305.
28. Yang X, Jansson PA, Pellme F, Laakso M, Smith U: Effect of the interleukin-6 (-174) G/C promoter polymorphism on adiponectin and insulin sensitivity. Obes Res 2005; 13: 813-817.